Hansa Biopharma Management
Management criteria checks 2/4
Hansa Biopharma's CEO is Søren Tulstrup, appointed in Mar 2018, has a tenure of 6.67 years. total yearly compensation is SEK27.51M, comprised of 30.7% salary and 69.3% bonuses, including company stock and options. directly owns 0.085% of the company’s shares, worth SEK2.02M. The average tenure of the management team and the board of directors is 4.8 years and 3.5 years respectively.
Key information
Søren Tulstrup
Chief executive officer
SEK 27.5m
Total compensation
| CEO salary percentage | 30.7% |
| CEO tenure | 6.7yrs |
| CEO ownership | 0.08% |
| Management average tenure | 4.8yrs |
| Board average tenure | 3.5yrs |
Recent management updates
Recent updates
Hansa Biopharma AB (publ) (STO:HNSA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Oct 20
Investors Appear Satisfied With Hansa Biopharma AB (publ)'s (STO:HNSA) Prospects As Shares Rocket 28%
Aug 24Hansa Biopharma AB (publ) (STO:HNSA) Analysts Just Slashed This Year's Revenue Estimates By 11%
Jul 23Hansa Biopharma AB (publ) (STO:HNSA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Jul 21Shareholders May Be Wary Of Increasing Hansa Biopharma AB (publ)'s (STO:HNSA) CEO Compensation Package
Jun 21Hansa Biopharma AB (publ) (STO:HNSA) Looks Just Right With A 32% Price Jump
May 21Some Analysts Just Cut Their Hansa Biopharma AB (publ) (STO:HNSA) Estimates
Apr 05Analyst Estimates: Here's What Brokers Think Of Hansa Biopharma AB (publ) (STO:HNSA) After Its Yearly Report
Feb 07Hansa Biopharma AB (publ) (STO:HNSA) Not Lagging Industry On Growth Or Pricing
Dec 28Newsflash: Hansa Biopharma AB (publ) (STO:HNSA) Analysts Have Been Trimming Their Revenue Forecasts
Oct 13Does Hansa Biopharma (STO:HNSA) Have A Healthy Balance Sheet?
Sep 22Investors Holding Back On Hansa Biopharma AB (publ) (STO:HNSA)
May 31Rock star Growth Puts Hansa Biopharma (STO:HNSA) In A Position To Use Debt
Apr 03Hansa Biopharma AB (publ) (STO:HNSA) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Feb 06Need To Know: The Consensus Just Cut Its Hansa Biopharma AB (publ) (STO:HNSA) Estimates For 2023
Feb 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -SEK 655m |
| Jun 30 2024 | n/a | n/a | -SEK 802m |
| Mar 31 2024 | n/a | n/a | -SEK 845m |
| Dec 31 2023 | SEK 28m | SEK 8m | -SEK 832m |
| Sep 30 2023 | n/a | n/a | -SEK 856m |
| Jun 30 2023 | n/a | n/a | -SEK 759m |
| Mar 31 2023 | n/a | n/a | -SEK 678m |
| Dec 31 2022 | SEK 26m | SEK 8m | -SEK 611m |
| Sep 30 2022 | n/a | n/a | -SEK 626m |
| Jun 30 2022 | n/a | n/a | -SEK 620m |
| Mar 31 2022 | n/a | n/a | -SEK 583m |
| Dec 31 2021 | SEK 26m | SEK 7m | -SEK 548m |
| Sep 30 2021 | n/a | n/a | -SEK 491m |
| Jun 30 2021 | n/a | n/a | -SEK 465m |
| Mar 31 2021 | n/a | n/a | -SEK 431m |
| Dec 31 2020 | SEK 21m | SEK 6m | -SEK 421m |
| Sep 30 2020 | n/a | n/a | -SEK 426m |
| Jun 30 2020 | n/a | n/a | -SEK 398m |
| Mar 31 2020 | n/a | n/a | -SEK 381m |
| Dec 31 2019 | SEK 11m | SEK 5m | -SEK 360m |
| Sep 30 2019 | n/a | n/a | -SEK 330m |
| Jun 30 2019 | n/a | n/a | -SEK 298m |
| Mar 31 2019 | n/a | n/a | -SEK 274m |
| Dec 31 2018 | SEK 8m | SEK 4m | -SEK 248m |
Compensation vs Market: Søren's total compensation ($USD2.57M) is above average for companies of similar size in the Swedish market ($USD473.05K).
Compensation vs Earnings: Søren's compensation has increased whilst the company is unprofitable.
CEO
Søren Tulstrup (59 yo)
6.7yrs
Tenure
SEK 27,505,000
Compensation
Mr. Søren Tulstrup, M.Sc, has been President and Chief Executive Officer of Hansa Biopharma AB (publ) (formerly known as Hansa Medical AB (publ)) since March 20, 2018. Mr. Tulstrup served as the Chief Exec...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & CEO | 6.7yrs | SEK 27.51m | 0.085% SEK 2.0m | |
| Chief Financial Officer | less than a year | no data | no data | |
| Senior VP & COO | 4.8yrs | no data | no data | |
| Chief Scientific and R&D Officer | less than a year | no data | no data | |
| Vice President of Finance & Administration | 5.5yrs | no data | no data | |
| VP & Head of Investor Relations | no data | no data | no data | |
| Senior VP & Chief Human Resources Officer | 5.8yrs | no data | no data | |
| VP & Head of Business Development | no data | no data | no data | |
| Head of Science | no data | no data | no data | |
| VP & Head of Medical Affairs | no data | no data | no data | |
| VP & Head of Research and Development | 3.6yrs | no data | no data |
4.8yrs
Average Tenure
55yo
Average Age
Experienced Management: HNSA's management team is considered experienced (4.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Director | less than a year | no data | no data | |
| Independent Director | 6.5yrs | SEK 413.00k | 0.0037% SEK 87.7k | |
| Independent Director | 5.5yrs | SEK 493.00k | 0.0015% SEK 34.9k | |
| Independent Chairman of the Board | 2.4yrs | SEK 1.14m | 0.036% SEK 858.5k | |
| Independent Director | 5.5yrs | SEK 591.00k | 0.0044% SEK 105.0k | |
| Independent Director | 3.5yrs | SEK 725.00k | no data | |
| Chairman of European Medical Advisory Board in Transplantation | no data | no data | no data | |
| Member - European Medical Advisory Board-Transplantation & US Medical Advisory Board-Transplantation | no data | no data | no data | |
| Member of European Medical Advisory Board in Transplantation | no data | no data | no data | |
| Chairman of US Medical Advisory Board in Transplantation | no data | no data | no data | |
| Member of US Medical Advisory Board in Transplantation | no data | no data | no data | |
| Director | less than a year | no data | no data |
3.5yrs
Average Tenure
59.5yo
Average Age
Experienced Board: HNSA's board of directors are considered experienced (3.5 years average tenure).